Phase II drugs under clinical investigation for the treatment of chronic constipation

Expert Opinion on Investigational Drugs

Volumn 23, Issue 11, 2014, Pages 1485-1497

  Mozaffari, Shilan ^a   Didari, Tina ^a   Nikfar, Shekoufeh ^b,c   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

5 hydroxytryptamine agonist; Bile acid transporter; Chronic constipation; Elobixibat; Investigational drug; Itopride; Naronapride; RM 131; Velusetrag

Indexed keywords

ACETYLCHOLINESTERASE; BILE ACID; DOPAMINE 2 RECEPTOR; ELOBIXIBAT; GHRELIN; ITOPRIDE; KWA 0711; MITEMCINAL; MOTILIN RECEPTOR; NARONAPRIDE; RM 131; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; TD 8954; UNCLASSIFIED DRUG; VELUSETRAG; YKP 10811; NEW DRUG;

CHRONIC DISEASE; CONSTIPATION; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WATER ABSORPTION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; GASTROINTESTINAL MOTILITY; PATHOPHYSIOLOGY; QUALITY OF LIFE;

ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS, PHASE II AS TOPIC; CONSTIPATION; DRUG DESIGN; DRUGS, INVESTIGATIONAL; GASTROINTESTINAL MOTILITY; HUMANS; QUALITY OF LIFE;

EID: 84911470277     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.932770     Document Type: Review

References (59)

1. Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of revalence and patterns of laxative use among adults with selfdefined constipation. Aliment Pharmacol Ther 2008;28:917-30
2. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011;106:1582-91. A comprehensive epidemiological systematic review on chronic constipation.
3. Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil 2008;20:121-9
4. Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol 2011;25:11-15. A useful review defining economic and social impacts of constipation and the effect of disorder on quality of life of patients.
5. Chang JY, Locke GR III, McNally MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol 2010;105:822-32
6. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
7. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol 2011;25:16-21
8. Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43. A useful article to understand the mechanisms of 5-hydroxytryptamine in affecting gastrointestinal motility in constipated patient.
9. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35:745-67.. A very informative article reviewing the safety of older and new generations of 5-hydroxytryptamine type-4 (5-HT4) receptor agonists.
10. Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014;39:239-53.. The most recent meta-analysis on newly introduced selective 5-HT4 receptor agonists efficacy and safety in patients with chronic constipation.
11. Tack J, Corsetti M. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Expert Opin Drug Metab Toxicol 2012;8:1327-35
12. Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf 2012;11:841-50
13. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010;55:1090-7
14. Lembo AJ, Johanson JF, Parkman HP, et al. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011;56:2639-45
15. Mozaffari S, Nikfar S, Abdollahi M. The safety of novel drugs used to treat irritable bowel syndrome. Expert Opin Drug Saf 2014. [Epub ahead of print]
16. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95
17. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25:599-608
18. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007;19:30-8
19. Palme M, Milner PG, Ellis DJ, et al. A novel gastrointestinal prokinetic, ATI-7505, increased spontaneous bowel movements (Sbms) in a phase II, randomized, placebo-controlled study of patients with chronic idiopathic constipation (CIC). Gastroenterology 2010;138:S128-9
20. Smith JA, Beattie DT, Marquess D, et al. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378:125-37
21. Beattie DT, Higgins DL, Ero MP, et al. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954. Vascul Pharmacol 2013;58:150-6
22. Beattie DT, Armstrong SR, Shaw JP, et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378:139-47
23. Shaw J-P, Beattie D, Cheong S-K, et al. Preclinical Pharmacokinetics of TD-5108, a selective, high intrinsic activity and orally bioavailable 5-HT4 receptor agonist. AAPS Ann Meet Expos. Presented at the annual meeting of the American Association of Pharmaceutical Scientists 2007;9:2422
24. Wong SL, Goldberg MR, Shaw J, et al. In healthy subjects, TD-5108, a selective high intrinsic activity 5-HT4 receptor agonist, shows dose-proportional pharmacokinetics and exhibits a profile consistent with once-daily dosing. Gastroenterology 2007;132:A374
25. Goldberg MR, Wong SL, Ganju J, et al. TD-5108, a selective 5-HT4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects. Gastroenterology 2007;132:A60
26. Manini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22:42-9
27. Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation-A 4-week, randomized, double-blind, placebocontrolled, dose-response study. Aliment Pharmacol Ther 2010;32:1102-12
28. SK biopharmaceuticals company. YKP10811 (chronic constipations). BIO-USA-Poster-11-YKP-1081 Available from: http://www.skbp.com and http://ri.search.yahoo.com/-ylt=A0LEVybUCEBTXiYAEAVXNyoA; -ylu=X3oDMTEzdjhiYXRpBHNlYw NzcgRwb3MDMQRjb2xv A2JmMQR2dGlkA1ZJUDM1N18x/RV=2/RE=1396734294/RO=10/RU=http %3a%2f%2fwww.kddf.org%2fcommon% 2ffile%2f%3fidx%3d1416%26fname% 3dBIO-USA-Poster-11-YKP-1081.pdf/RK=0/RS=ek2s9h08t6PaljYg SaTeaA85GWM-
29. SK Chemicals Co.,Ltd. Efficacy and safety of ykp10811 in subjects with irritable bowel syndrome with constipation. 2014. Available from: http://www.clinicaltrial.gov/ct2/show/NCT02082457?term=NCT02082457&rank=1
30. SK Life Science. A Phase 2 study to evaluate pharmacodynamics of ykp10811 in patients with chronic or functional constipation. 2012. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01523184? term=NCT01523184&rank=1
31. SK Life Science. A multicenter, doubleblind, randomized, placebo-controlled, 12-week, dose-range-finding trial of ykp10811 capsules administered once daily to subjects with chronic idiopathic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01989234? term=NCT01989234&rank=1
32. Beattie DT, Armstrong SR, Vickery RG, et al. The pharmacology of TD-8954, a potent and selective 5-ht(4) receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol 2011;2:25. This article contains valuable information about TD-8954 as a new 5-HT4 receptor agonist.
33. Beattie DT, Vickery RG, Arm-strong SR, et al. TD-8954 is a highly potent and selective 5-HT4 receptor agonist with potential utility in disorders of reduced gastrointestinal motility. Gastroenterology 2008;134:A-247
34. Theravance, Inc. A Phase 1, multiple intravenous dose study to examine the safety, tolerability, and pharmacokinetics of intravenous TD-8954, a 5-HT4 receptor agonist, in healthy subjects. 2012. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01644240? term=NCT01644240&rank=1
35. Simrén M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation-A double-blind study. Aliment Pharmacol Ther 2011;34:41-50
36. Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011;106:1803-12
37. Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011;106:2154-64
38. Ferring Pharmaceuticals. 12 Week efficacy and safety trial followed by a 4 week withdrawal period for patients with chronic idiopathic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01833065? term=NCT01833065&rank=1
39. Ferring Pharmaceuticals. 26 Week efficacy and safety trial for patients with chronic idiopathic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/record/NCT01827592? term=NCT01827592&rank=1
40. Albireo. Study of A3309 in patients with chronic idiopathic constipation. 2009. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01007123? term=NCT01007123&rank=1
41. Mayo Clinic. Effect of ileal bile acid transporter inhibitor in functional constipation. 2009. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01038687?term=NCT01038687& rank=1
42. Ferring Pharmaceuticals. Safety and tolerability extension trial for patients with chronic idiopathic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01895543? term=NCT01895543&rank=1
43. Kissei Pharmaceutical Co., Ltd. A singleblind, dose-tapering study of KWA-0711 in patients with chronic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/record/NCT01937663? term=NCT01937663&rank=1
44. Kissei Pharmaceutical Co., Ltd. A singleblind, dose-titration study of KWA-0711 in patients with chronic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/record/NCT01938196? term=NCT01938196&rank=1
45. Kissei Pharmaceutical Co., Ltd. A exploratory study of kwa-0711 in patients with chronic idiopathic constipation (CIC). 2012. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01600001? term=NCT01600001&rank=1
46. Charoenthongtrakul S, Giuliana D, Longo KA, et al. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists. J Pharmacol Exp Ther 2009;329:1178-86
47. Shimizu Y, Chang EC, Shafton AD, et al. Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat. J Physiol 2006;576:329-38
48. Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013;36:41-8
49. Rhythm Pharmaceuticals, Inc. A Phase 2 study to evaluate the safety and efficacy of rm-131 in patients with parkinson's disease & chronic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/record/NCT01955616? term=NCT01955616&rank=1
50. Rhythm Pharmaceuticals, Inc. Phase 2 study to evaluate safety and efficacy of rm-131 administered to patients with chronic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01781104? term=NCT01781104&rank=1
51. Iwanaga Y, Miyashita N, Saito T, et al. Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs. Jpn J Pharmacol 1996;71:129-37
52. Huang X, Lv B, Zhang S, et al. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol 2012;18:7371-7
53. Lim HC, Kim YG, Lim JH, et al. Effect of itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro. Yonsei Med J 2008;49:472-8
54. Tsubouchi T, Saito T, Mizutani F, et al. Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. J Pharmacol Exp Ther 2003;306:787-93
55. Chiba T, Tokunaga Y, Ikeda K, et al. Effects of itopride hydrochloride and ranitidine in patients with functional dyspepsia: comparison between prokinetic and acid suppression therapies. Hepatogastroenterology 2007;54:1878-81
56. Shanghai Jiao Tong University School of Medicine. Itopride as an adjuvant for bowel preparation in patients with chronic constipation is effective. 2012. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01513811? term=NCT01513811&rank=1
57. Ozaki K, Sudo H, Muramatsu H, et al. Mitemcinal (GM-611), an orally active motilin receptor agonist, accelerates colonic motility and bowel movement in conscious dogs. Inflammopharmacology 2007;15:36-42
58. Sudo H, Ozaki K, Muramatsu H, et al. Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools. Neurogastroenterol Motil 2007;19:318-26
59. Available from: https://pubchem.ncbi.nlm.nih.gov